ClinicalTrials.gg
CompletedNCT06589726Updated Dec 19, 2024

A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants

A Phase 1 interventional study of Placebo and Moxifloxacin in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess potential effects of enpatoran on cardiac repolarization (i.e. prolongation of QT interval).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are overtly healthy, as determined by medical evaluation, including no abnormality identified on medical history, physical examination, vital signs, 12-lead , or laboratory evaluation and no active clinically significant disorder, condition, infection, or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion
  • Participants have a body weight within the range 50.0 to 100.0 kilograms (kg) (inclusive) and (BMI) within the range 19.0 to 30.0 kilograms per square meter (kg/m\^2) (inclusive)
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion criteria:

  • History or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, musculoskeletal, genitourinary, immunological, dermatological, connective tissue, psychiatric (due to rare risk of hallucinations, agitation, and activation of psychosis), and other diseases or disorders, and epilepsy, as determined by medical evaluation
  • Individuals with diagnosis of hemochromatosis, Wilson´s disease, alpha 1 antitrypsin deficiency, or any other chronic liver disease including Gilbert's disease
  • Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery within 6 months prior to the first administration of study intervention
  • History of (e.g. hematologic, skin, solid tumor) less than or equal to (\<=) 10 years prior to Screening
  • History of chronic or recurrent acute infection or any bacterial, viral, parasitic, or fungal infections within 30 days prior to Screening and at any time between Screening and admission to CRU, or hospitalization due to infection within 6 months prior to the first administration of study intervention
  • History of shingles within 12 months prior to Screening
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1: A-B-C-D

    Participants will receive a single oral dose of placebo matched to enpatoran (Treatment A) in treatment period 1, followed by a single oral dose of moxifloxacin tablet (Treatment B) in treatment period 2, followed by a single oral low dose of enpatoran tablet (Treatment C) in treatment period 3, followed by a single oral high dose of enpatoran tablet (Treatment D) in treatment period 4. There will be a washout period of at least 10 days between each treatment period.

    Drug: Placebo · Drug: Moxifloxacin · Drug: Enpatoran low dose · Drug: Enpatoran high dose

  • Experimental
    Treatment Sequence 2: B-D-A-C

    Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in treatment period 1, followed by a single oral high dose of enpatoran tablet (Treatment D) in treatment period 2, followed by a single oral dose of placebo matched to enpatoran (Treatment A) in treatment period 3, followed by a single oral low dose of enpatoran tablet (Treatment C) in treatment period 4. There will be a washout period of at least 10 days between each treatment period.

    Drug: Placebo · Drug: Moxifloxacin · Drug: Enpatoran low dose · Drug: Enpatoran high dose

  • Experimental
    Treatment Sequence 3: C-A-D-B

    Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in treatment period 1, followed by a single oral dose of placebo matched to enpatoran (Treatment A) in treatment period 2, followed by a single oral high dose of enpatoran tablet (Treatment D) in treatment period 3, followed a by single oral of moxifloxacin tablet (Treatment B) in treatment period 4. There will be a washout period of at least 10 days between each treatment period.

    Drug: Placebo · Drug: Moxifloxacin · Drug: Enpatoran low dose · Drug: Enpatoran high dose

  • Experimental
    Treatment Sequence 4: D-C-B-A

    Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in treatment period 1, followed by a single oral low dose of enpatoran (Treatment C) in treatment period 2, followed by a single oral dose of moxifloxacin tablet (Treatment B) in treatment period 3, followed by a single oral dose of placebo matched to enpatoran (Treatment A) in treatment period 4. There will be a washout period of at least 10 days between each treatment period.

    Drug: Placebo · Drug: Moxifloxacin · Drug: Enpatoran low dose · Drug: Enpatoran high dose

Interventions

  • DrugPlacebo

    Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.

  • Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.

  • Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.

    Also known as: M5049

  • Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.

    Also known as: M5049

06

What researchers measure

Primary outcomes

  1. Placebo-Corrected Change from Baseline in Heart Rate-Corrected QT Interval by Fridericia's Formula (QTcF) for Enpatoran

    Time frame: Pre-dose on Day 1 (baseline) up to 24 hours post-dose

Secondary outcomes

  1. Placebo-Corrected Change from Baseline in Heart Rate-Corrected QT Interval by Fridericia's Formula (QTcF) for Moxifloxacin

    Time frame: Pre-dose on Day 1 (baseline) up to 24 hours post-dose

  2. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 72 days

  3. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) by Severity

    Time frame: Up to approximately 72 days

  4. Number of Participants with Abnormal Laboratory Parameters, Vital Signs and 12-Lead Electrocardiogram (ECG) Findings

    Time frame: Up to approximately 72 days

  5. ECG Parameters: QT Interval, heart rate-corrected QT interval (QTc), individual corrected QT interval (QTcI), PR Interval, QRS interval and RR Interval

    Time frame: Pre-dose up to 24 hours post-dose

  6. ECG Parameter: Heart Rate (HR)

    Time frame: Pre-dose up to 24 hours post-dose

  7. Number of Participants with T-wave Morphology Changes and U-wave Presence

    Time frame: Pre-dose up to 24 hours post-dose

  8. Pharmacokinetic (PK) Plasma Concentrations of Enpatoran

    Time frame: Pre-dose up to 24 hours post-dose

  9. Pharmacokinetic (PK) Plasma Concentrations of Moxifloxacin

    Time frame: Pre-dose up to 24 hours post-dose

07

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, Germany
08

References and documents

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website http://bit.ly/IPD21

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Dec 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Sep 10, 2024
Primary completionActual
Dec 2, 2024
CompletionActual
Dec 2, 2024
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06589726
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 10, 2024
Primary completion
Dec 2, 2024
Completion
Dec 2, 2024
Last update
Dec 19, 2024

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enpatoran

Start the discussion